RT Journal Article
SR Electronic
T1 Early Release Estimates for SARS-CoV-2 Prevalence and Antibody Response Interim Weighting for Probability-Based Sample Surveys
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.15.20195099
DO 10.1101/2020.09.15.20195099
A1 Bradley, Heather
A1 Fahimi, Mansour
A1 Sanchez, Travis
A1 Lopman, Ben
A1 Frankel, Martin
A1 Kelley, Colleen F.
A1 Rothenberg, Richard
A1 Siegler, Aaron J
A1 Sullivan, Patrick S
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.09.15.20195099.abstract
AB Many months into the SARS-CoV-2 pandemic, basic epidemiologic parameters describing burden of disease are lacking. To reduce selection bias in current burden of disease estimates derived from diagnostic testing data or serologic testing in convenience samples, we are conducting a national probability-based sample SARS-CoV-2 serosurvey. Sampling from a national address-based frame and using mailed recruitment materials and test kits will allow us to estimate national prevalence of SARS-CoV-2 infection and antibodies, overall and by demographic, behavioral, and clinical characteristics. Data will be weighted for unequal selection probabilities and non-response and will be adjusted to population benchmarks. Due to the urgent need for these estimates, expedited interim weighting of serosurvey responses will be undertaken to produce early release estimates, which will be published on the study website, COVIDVu.org. Here, we describe a process for computing interim survey weights and guidelines for release of interim estimates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNIH NIAID 3R01AI143875-02S1, Woodruff FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Emory University Institutional Review Board (protocol 00000695)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collection is on-going but interim estimates will be available on the study website in the coming months.